Clearbridge Investments LLC Reduces Position in Insulet Corporation $PODD

Clearbridge Investments LLC lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,387,527 shares of the medical instruments supplier’s stock after selling 79,747 shares during the period. Clearbridge Investments LLC owned about 1.97% of Insulet worth $394,391,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Cookson Peirce & Co. Inc. bought a new stake in shares of Insulet during the fourth quarter valued at approximately $300,000. Havemeyer Place LP bought a new stake in shares of Insulet during the fourth quarter valued at approximately $641,000. BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of Insulet by 137.5% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 30,534 shares of the medical instruments supplier’s stock valued at $8,679,000 after acquiring an additional 17,678 shares in the last quarter. Pinebridge Investments LLC bought a new stake in shares of Insulet during the fourth quarter valued at approximately $5,433,000. Finally, WINTON GROUP Ltd raised its stake in shares of Insulet by 14.8% during the fourth quarter. WINTON GROUP Ltd now owns 4,692 shares of the medical instruments supplier’s stock valued at $1,334,000 after acquiring an additional 606 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Robert W. Baird decreased their price target on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $280.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Oppenheimer decreased their price target on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Truist Financial decreased their price target on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Jefferies Financial Group decreased their price target on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.04.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is owned by company insiders.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $153.22 on Friday. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of 35.63, a price-to-earnings-growth ratio of 1.21 and a beta of 1.13. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a 50 day moving average of $175.73 and a 200 day moving average of $238.90.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.